Since 'constitutive activation' of STAT1 was first described in Epstein-Barr virus (EBV)-immortalized lymphoblastoid cell lines (LCLs), there has been controversy regarding the molecular identity of the STAT1 DNA-binding complex found in these cells. The post-translational modifications of STAT1 in LCLs have been analysed and an LMP1-induced STAT1 DNA-binding complex, different from that generated by alpha interferon (IFN) stimulation and not involving tyrosine phosphorylation, is demonstrated. STAT1 is serine-phosphorylated downstream of PI3K and MEK in LCLs and this modification restricts IFN-stimulated STAT1-DNA binding. These data suggest that EBV induces a distinct form of DNA-bound STAT1 in virus-infected cells.
INTRODUCTION
Epstein-Barr virus (EBV) is a lymphotropic c-herpesvirus that infects .90 % of the world's adult population. Although the effects are asymptomatic in most cases, due to the presence of circulating cytotoxic T lymphocytes (Rickinson & Moss, 1997) , EBV infection is also associated with the onset of malignancies such as Burkitt's lymphoma, Hodgkin's lymphoma and post-transplant lymphoproliferative disease (PTLD) (Rickinson & Kieff, 1996) .
One of the main characteristics of EBV is its ability to establish viral latency. Three types of latency have been described, each of which displays a different subset of EBV latent genes. In type I latency, which is seen in EBVassociated Burkitt's lymphoma, only one viral protein, EBNA-1, is expressed. In type II latency, which is seen in Hodgkin's lymphoma and nasopharyngeal carcinoma, EBNA-1 and three viral latent membrane proteins (LMPs), LMP1, LMP2A and LMP2B, are expressed. In type III latency, which is seen in PTLD, nine viral proteins are expressed (EBNA-1, EBNA-2, EBNA-3A, EBNA-3B, EBNA-3C, EBNA-LP, LMP1, LMP2A and LMP2B) (Rickinson & Kieff, 1996) .
EBV is capable of transforming and immortalizing primary B lymphocytes into lymphoblastoid cell lines (LCLs). LCLs display type III latency and thus act as a cellular model for PTLD (Rickinson & Kieff, 1996) . Among the nine viral proteins that are expressed in type III latency, LMP1 is essential to the immortalization process (Kaye et al., 1993; Kilger et al., 1998) . LMP1 mimics a constitutively activated CD40 receptor (Gires et al., 1997) and contains two specialized C-terminal domains (CTAR1 and CTAR2) that trigger cellular signalling (Eliopoulos & Young, 2001) . Signal transducer and activator of transcription 1 (STAT1) expression has been shown to be induced by LMP1 and is known to be mediated by the co-operation of these two C-terminal domains (Richardson et al., 2003; Zhang et al., 2004) .
STAT1 is a transcription factor that was originally discovered as a target of interferon (IFN) activation. It belongs to a family of latent transcription factors that become activated in response to extracellular ligands such as the cytokine IFN-a. Activation involves a phosphorylation cascade that enables STATs to dimerize, translocate to the nucleus and activate gene transcription at gammaactivated sequence (GAS) and IFN-stimulated response elements located in the promoters of IFN-responsive genes . The key post-translational modification involved is tyrosine phosphorylation at residue 701, although other modifications that can regulate STAT activity exist. These include serine phosphorylation at residue 727, which has been shown to be important for STAT1 transactivation (Decker & Kovarik, 2000) , arginine methylation (Mowen et al., 2001 ) and lysine acetylation (Kramer et al., 2006) . that STAT1 is not constitutively tyrosine-phosphorylated in LCLs, but is capable of being tyrosine-phosphorylated in response to IFN-a (Dupuis et al., 2001; Zhang et al., 2004) . However, other studies disagree with this and have reported that STAT1 is constitutively tyrosine-phosphorylated in LCLs, and a mechanism has even been described involving an indirect autocrine loop of IFN secretion (Fagard et al., 2002; Najjar et al., 2005; Nepomuceno et al., 2002) . As STATs are capable of regulating the expression of apoptotic and cell-cycle proteins such as Bcl-X L and cyclin D1 (Bowman et al., 2000) , the role of STAT1 in the progression of EBV-associated malignancy may be vital. This is highlighted by recent evidence suggesting that STAT1 acts as a tumour promoter rather than a tumour suppressor in the development of leukaemia (Kovacic et al., 2006) . Therefore, the regulation of STAT1 by specific posttranslational modifications may provide a key insight into its activity in EBV-associated malignancy.
This study was initiated to investigate the post-translational modifications of STAT1 in EBV-immortalized LCLs. We have shown that STAT1 is only tyrosine-phosphorylated following stimulation with IFN-a, but is capable of binding DNA. This effect is driven specifically by the oncogene LMP1. STAT1 was found to be constitutively serinephosphorylated, but lacked detectable lysine acetylation. This modification is regulated by two distinct pathways, PI3K and MEK, and appears to repress the DNA binding of STAT1 following IFN-a stimulation.
METHODS
Cell lines and culture. Kit 225 is a human interleukin-2 (IL-2)-dependent leukaemic T-cell line (Hori et al., 1987) . KEM LCL is a patient-derived EBV-immortalized LCL (Rowe et al., 1995) . EB LCL is an EBV-immortalized LCL that was derived in house. BL41 is a patient-derived EBV-negative Burkitt's lymphoma cell line. BL41+B95.8 is the same line that has been infected in vitro with the B95.8 strain of EBV. IARC-171 is an EBV-immortalized LCL obtained from the same patient as BL41 (Rowe et al., 1986) . DG75 is an EBV-negative Burkitt's lymphoma cell line (Ben-Bassat et al., 1977) . DG75 tTA LMP1 is a stable transfectant of the DG75 cell line capable of tetracycline-regulated LMP1 expression (Floettmann et al., 1996) . All cell lines were cultured in RPMI 1640 medium supplemented with 10 % fetal calf serum, 2 mM L-glutamine and antibiotics (200 U penicillin ml 21 and 200 mg streptomycin ml
21
) and were maintained at 37 uC in a 5 % CO 2 humidified incubator. Tetracycline (1 mg ml
) was used to silence tetracycline-regulated LMP1 expression in the DG75 tTA LMP1 cell line. The Kit 225 T-cell line was cultured in medium supplemented with 20 ng IL-2 ml 21 (Chiron).
Generation of nuclear extracts. Nuclear extracts were prepared by using a method described previously (Brennan & O'Neill, 1996) . Following application of any stimuli or inhibitors, 1610 7 cells were first washed in 1 ml hypotonic buffer [10 mM HEPES (pH 7.9), 1.5 mM MgCl 2 , 10 mM KCl] and centrifuged at 13 000 r.p.m. for 1 min (Heraeus Biofuge). Cells were then lysed in 100 ml hypotonic buffer supplemented with 1 mM PMSF, 1 : 100 dilutions of phosphatase inhibitor cocktails I and II (Sigma; P-2850 and P-5726, respectively) and 0.1 % Nonidet P40 detergent and placed on ice for 5 min. Following centrifugation (13 000 r.p.m., 5 min, 4 uC; Heraeus Biofuge), the supernatant was retrieved, representing a cytosolic extract. Nuclear extracts were prepared by incubating the remaining pellet for 15 min in 50 ml high-salt buffer [20 mM HEPES (pH 7.9), 420 mM NaCl, 1.5 mM MgCl 2 , 25 % glycerol] supplemented with 1 mM PMSF and 1 : 100 dilutions of phosphatase inhibitor cocktails I and II immediately prior to use. Following centrifugation (13 000 r.p.m., 5 min, 4 uC; Heraeus Biofuge), the supernatant was collected, representing the nuclear extract. For extracts prepared specifically for application in an electrophoretic mobility-shift assay (EMSA), 50 ml storage buffer [10 mM HEPES (pH 7.9), 50 mM KCl, 0.2 mM EDTA, 20 % glycerol] was also added to the nuclear extract. All extracts were then stored at 220 uC.
Generation of total cell lysates, SDS-PAGE and Western blotting. Cells were counted on a haemocytometer and resuspended in 50 ml 16 PBS per 10 6 cells. An equal volume of 26 gel sample buffer (GSB) [0.1 M Tris/HCl (pH 6.8), 0.2 M dithiothreitol (DTT), 4 % SDS, 20 % glycerol, 0.1 % bromophenol blue] was then added. Cells were sonicated by using a W0385 sonicator (HeatsystemsUltrasonics Inc.) and, following sonication, samples were heated at 100 uC for 5 min. Proteins were then separated by SDS-PAGE and transferred onto PVDF membranes (Amersham Biosciences) for immunoblotting using a previously described alkaline phosphatase chemiluminescent detection protocol (Rowe & Jones, 2001 ). Antibodies to phospho-STAT1 (Y701) (sc-7988-R), phospho-STAT1 (S727) (sc-16570-R), pan-STAT1 (sc-346) and phospho-ERK1/2 (Y204) (sc-7383) ERK1/2 (sc-93) were from Santa Cruz Biotechnology and were used at a concentration of 0.2 mg ml
. Antibodies to phospho-S6 (S235/236) (#2211) and pan-S6 (#2212) were from Cell Signaling Technology and were used at a 1 : 1000 dilution of the stock supplied. The antibody to acetyl-lysine ( # 06-933) was from Upstate Technology and was used as a 1 : 1000 dilution of the stock supplied. The antibody to actin (A-2066) was from Sigma and was used as a 1 : 1000 dilution of the stock supplied. The primary antibody to LMP1 (CS1-4) has been described previously (Rowe et al., 1987) and was used as a 1 : 1000 dilution.
DNA-affinity precipitation. Nuclear extracts were generated as described above and diluted to 1 ml with salt-free buffer [50 mM Tris/HCl (pH 8), 0.25 mM EDTA, 10 mM NaF, 10 % glycerol, 0.5 mM PMSF, 10 ml phosphatase inhibitor cocktails I and II ml 21 , 5 mM DTT, 1 mM NaVO 4 ]. By using an adapted version of the method of Beadling et al. (1996) , streptavidin-conjugated agarose beads (30 ml of 1 : 1 slurry) and biotinylated double-stranded GRR oligonucleotide (1 mg) were added to the nuclear extract, which was rotated for 1 h at 4 uC. The mixture was centrifuged at 6000 r.p.m. for 5 min (Heraeus Biofuge) and the supernatant was removed. The beads were then washed three times in a wash buffer [50 mM Tris/ HCl (pH 8), 0.25 mM EDTA, 10 mM NaF, 10 % glycerol, 0.5 mM PMSF, 40 mM NaCl, 5 mM DTT] and the proteins were eluted from the beads by the addition of 26 GSB. Eluted proteins were then separated by SDS-PAGE, transferred onto PVDF membranes and analysed by using specific antibodies. The GRR oligonucleotide (GTATTTCCCAGAAAAGGAAC) corresponds to a STAT consensus sequence derived from the FccR1-GAS.
EMSA. Nuclear extracts of 2610 7 cells were generated and quantified by using the Bradford method. Using a previously described method (Brennan & O'Neill, 1996) , 10 mg nuclear extract was incubated with either 2 ng 32 P-radiolabelled GRR oligonucleotide, mutant GRR (mGRR) (GTATGTCCCAGAGAAGGAAC) or SIE oligonucleotide (GTGCATTTCCCGTAAATCTTGTCTACA) (sc-2535; Santa Cruz Biotechnology), generated by T4 polynucleotide labelling. For supershift assays, the nuclear extracts were pre-incubated for 30 min with 2 mg antibody to STAT1 from Santa Cruz Biotechnology (sc-592 X) and BD Transduction Laboratories (610119). For cold competitor assays, the nuclear extracts were pre-incubated for 30 min with 100 ng cold GRR oligonucleotide. The binding reaction was performed in binding buffer [10 mM Tris/HCl (pH 7.5), 1 mM EDTA, 100 mM NaCl, 4 % glycerol, 0.1 mg BSA ml 21 , 5 mM DTT] with the addition of 2 ng poly(dIdC) (Amersham Biosciences) for 30 min at room temperature prior to separation of protein-DNA complexes by using a native 4 % polyacrylamide gel.
Immunoprecipitation. Nuclear extracts were generated as described above and diluted to 1 ml with salt-free buffer [50 mM Tris/HCl (pH 8.0), 0.25 mM EDTA, 10 mM NaF, 10 % glycerol, 0.5 mM PMSF, 10 ml phosphatase inhibitor cocktails I and II ml
, 5 mM DTT, 1 mM NaVO 4 ]. Forty microlitres (1 : 1 slurry) of pre-washed STAT1 antibody (sc-346; Santa Cruz Biotechnology)-or ATF-3 antibody (sc-188; Santa Cruz Biotechnology)-bound Sepharoseprotein G beads was added to the nuclear extract and rotated at 4 uC for 120 min. The antibody-conjugated beads were collected by centrifugation (6000 r.p.m., 3-4 s, 4 uC; Heraeus Biofuge) and washed two times in cold lysis buffer [50 mM HEPES (pH 7.9), 2 mM EDTA, 250 mM NaCl, 0.1 % Nonidet P40 detergent] and two times in cold PBS. Antibody-bound proteins were eluted by the addition of 25 ml PBS and 25 ml 26 GSB and heating at 100 uC for 5 min.
Plasmids. The GRR (5)-luc reporter construct, containing five copies of the STAT consensus sequence derived from the FccR1-GAS upstream of a firefly luciferase gene, has been described previously (Beadling et al., 1996; Richardson et al., 2003) . The phRL-SV40 reporter contains a synthetic Renilla luciferase gene downstream of a T7 promoter and was obtained from Promega (E-6261).
Transient transfection and luciferase reporter assay. Cells ( 1610 7 ) were transiently transfected by electroporation using a Bio-Rad Gene Pulser II electroporator at 270 V and 950 mF at room temperature in 500 ml RPMI 1640 medium. Following transfection, cells were seeded in 3.5 ml fresh RPMI 1640 medium and incubated for 20 h at 37 uC in a 5 % CO 2 humidified incubator. To assay luciferase activity from the reporter constructs, cells were washed in chilled PBS and lysed in 100 ml 16 passive lysis buffer provided within the Promega Dual Luciferase reporter assay kit (E-1910) . Lysates were clarified by centrifugation (13 000 r.p.m., 1 min; Heraeus Biofuge) and 50 ml of supernatant was then assayed for firefly and Renilla luciferase levels in a 96-well plate by using reagents supplied with the kit. Light release was integrated for 10 s and measured by using a FLUOstar OPTIMA luminometer.
Inducing expression of LMP1 in the DG75 tTA LMP1 cell line.
The stable transfectant DG75 tTA LMP1 was maintained under drug selection with 1 mg tetracycline ml 21 until required. Prior to an experiment, cells were washed five times in RPMI 1640 medium and were recultured in the presence or absence of 1 mg tetracycline ml 21 for a period of 72 or 96 h. Total cell lysates and nuclear extracts were generated as described above.
RESULTS

STAT1 is tyrosine-phosphorylated following IFN-a stimulation, but is capable of binding DNA
We have previously demonstrated DNA binding of STAT1 in EBV-immortalized LCLs (Richardson et al., 2003) , but have not determined the post-translational modifications of the increased levels of STAT1 found in these cells. Given the conflicting literature, we first analysed STAT1 tyrosine phosphorylation in a range of LCLs that were either untreated or stimulated with IFN-a for 30 min. Total cell lysates were analysed by SDS-PAGE and Western blotting using specific antibodies. Fig. 1(a) illustrates the absence of detectable STAT1 tyrosine phosphorylation in two LCLs, KEM and EB, a result also seen in three other LCLs including IARC-171 (not shown). Only after stimulation with IFN-a was STAT1 tyrosine-phosphorylated, as has been reported previously (Dupuis et al., 2001; Zhang et al., 2004) .
Transcriptional regulation by STAT1 is dependent on its ability to bind DNA in the nucleus. We investigated STAT1 DNA binding in a set of B-cell lines differing in their EBV gene-expression profile. These lines include: BL41, an EBVnegative Burkitt's lymphoma; BL41+B95.8, the same line that has been infected in vitro with the B95.8 strain of EBV; and IARC-171, an EBV-immortalized LCL (Rowe et al., 1986) . STAT1 DNA binding was measured in untreated or IFN-a-stimulated cells by using DNA-affinity precipitation. DNA-bound proteins were analysed by SDS-PAGE and Western blotting using specific antibodies to tyrosinephosphorylated and pan-STAT1 (Fig. 1b) . STAT1 DNA binding was observed in the BL41 and BL41+B95.8 cell lines only after IFN-a stimulation, whereas in the IARC-171 LCL, it was seen in both untreated and IFN-astimulated cells.
To confirm this constitutive binding, we investigated STAT1 DNA binding in the same cell lines by EMSA. Cells were either untreated or stimulated with IFN-a, and 10 mg nuclear extract was incubated with 2 ng 32 Pradiolabelled GRR probe or SIE oligonucleotide probe, representing a consensus sequence for the binding of Sis-inducible factor (Sadowski et al., 1993) . Protein-DNA complexes were then separated by using a native 4 % polyacrylamide gel and visualized by autoradiography (Fig. 1c) . Protein-DNA complexes are seen on both probes in the IFN-a-stimulated BL41 and BL41+B95.8 cell lines. In the IARC-171 LCL, these complexes are seen in both untreated and IFN-a-stimulated cells, an observation that is consistent with the data in Fig. 1(b) . This suggested that, in LCLs, STAT1 can bind DNA in the absence of detectable tyrosine phosphorylation. This observation was consistent with previously published data that demonstrated LMP1-induced STAT1 DNA binding (Richardson et al., 2003) .
STAT1 forms a distinct DNA-binding complex
To elucidate the identity of the protein-DNA complexes in IARC-171 LCLs that can be observed in Fig. 1(c) , a STAT1 antibody (sc-592 X) was pre-incubated with nuclear extracts of both untreated and IFN-a-stimulated IARC-171 LCL cells before 32 P-radiolabelled GRR or SIE probe was added (Fig. 2a) . Although no reduction in electrophoretic mobility was observed following pre-incubation with the STAT1 antibody, a reduction in the intensity of the protein-DNA complexes was seen. This indicated that the antibody was preventing a full protein-DNA interaction and thus identified STAT1 as a component of the DNA-bound protein with both probes. The specificity of this complex was ascertained through incubation of a mutant 32 P-radiolabelled GRR probe and through competitive binding with an excess of cold GRR competitor probe (Fig. 2b) . In order to confirm fully that the protein-DNA complex contained STAT1, untreated and IFN-astimulated IARC-171 LCL cells were pre-incubated with a different STAT1 antibody (610199; BD Transduction Laboratories) before 32 P-radiolabelled GRR probe was added (Fig. 2c) . The supershift seen with the STAT1 antibody reiterated its presence in the DNA-binding complex.
We investigated STAT transcriptional activity in untreated IARC-171 LCL cells by transiently transfecting them with a STAT luciferase reporter. Cells were transfected with either 20 mg empty vector-luc reporter or increasing amounts (5, 10 or 20 mg) of GRR (5)-luc reporter. Fig. 2(d) shows that STAT transcriptional activity increased, at levels higher than the empty-vector control, with rising amounts of the STAT reporter.
From these data, we conclude that EBV-immortalized LCLs contain a constitutive STAT1 DNA-binding complex, unphosphorylated at tyrosine 701, that can probably stimulate transcriptional activation.
LMP1 induces STAT1 protein expression, nuclear translocation and DNA binding without triggering tyrosine phosphorylation LMP1 has been shown to be responsible for inducing STAT1 expression and transcriptional activity in EBVinfected B lymphocytes (Richardson et al., 2003; Zhang et al., 2004) . Given that we observed constitutive STAT1 DNA binding in the absence of tyrosine phosphorylation, we investigated whether this effect was LMP1-specific. In order to study the impact of LMP1 in a cellular context, we sought use of a stable transfectant of an EBV-negative Burkitt's lymphoma cell line in which LMP1 expression is controlled by a tetracycline-regulated LMP1 expression vector (Floettmann et al., 1996) . This cell line, DG75 tTA LMP1, allows LMP1 to be induced in an EBV-negative B-cell system through removal of tetracycline. To show successful induction of LMP1, total cell lysates were generated of cells cultured in the presence or absence of tetracycline for 72 or 96 h. The lysates were analysed by SDS-PAGE and Western blotting using specific antibodies to LMP1. Fig. 3(a) shows the presence of LMP1 in the cells that were cultured in the absence of tetracycline for 72 or 96 h, but not in those cultured with tetracycline. IARC-171 was used as a positive control for LMP1 expression and actin was used as a loading control. To see whether LMP1 induces STAT1 expression, nuclear translocation and tyrosine phosphorylation, nuclear extracts were generated of DG75 tTA LMP1 cells cultured in the presence or absence of tetracycline for 72 or 96 h. These cells were also either stimulated with IFN-a or left untreated. Nuclear extract (10 mg) was then analysed by SDS-PAGE and Western blotting using specific antibodies. Fig. 3(b) shows that LMP1 induces STAT1 nuclear expression, but does not trigger tyrosine phosphorylation. Only Fig. 1 . STAT1 is tyrosine-phosphorylated in LCLs after IFN-a stimulation, but can bind DNA in the absence of stimulation. (a) Total cell lysates were generated from three cell lines: Kit 225, KEM LCL and EB LCL. These cell lines were either unstimulated or incubated with IFN-a (1000 IU) for 30 min. These lysates were analysed by SDS-PAGE and Western blotting using antibodies specific to phospho-STAT1 (Y701), pan-STAT1 and LMP1. The Kit 225 T-cell line was used as a positive control for the presence of tyrosinephosphorylated STAT1 following IFN-a stimulation, and LMP1 detection was used as a positive marker for EBV. (b) STAT1 DNA binding was measured in the BL41, BL41+B95.8 and IARC-171 cell lines by using a DNA-affinity precipitation assay. These cell lines were either unstimulated or incubated with IFN-a (1000 IU) for 30 min. DNA-bound proteins were analysed by SDS-PAGE and Western blotting using antibodies specific to phospho-STAT1 (Y701) and pan-STAT1. Typically, 1¾10 7 cell equivalents were applied to each lane of the gel. These results are representative of four separate experiments. (c) STAT1 DNA binding was measured in the BL41, BL41+B95.8 and IARC-171 cell lines by using an EMSA. These cell lines were either unstimulated or incubated with IFN-a (1000 IU) for 30 min. Nuclear extract (10 mg) was then incubated with 2 ng 32 P-radiolabelled GRR oligonucleotide or SIE oligonucleotide probe. Protein-DNA complexes were separated by using a native 4 % polyacrylamide gel and visualized by autoradiography. Only protein-DNA complexes are shown, as free probe has been removed from the figure. The arrow indicates a specific protein-DNA complex. The results shown are representative of three separate experiments.
after IFN stimulation was tyrosine phosphorylation observed. This shows that LMP1 elevates STAT1 expression in LCLs, but does not induce tyrosine phosphorylation. The impact of LMP1 on STAT1 DNA binding in LCLs was investigated by using an EMSA (Fig. 3c) . DG75 tTA LMP1 cells were cultured in the presence or absence of tetracycline for 72 or 96 h and were either incubated with IFN-a or left unstimulated. Nuclear extract (10 mg) was incubated with 2 ng 32 P-radiolabelled GRR probe, and any protein-DNA complexes formed were then separated by using a native 4 % polyacrylamide gel and visualized by autoradiography. Fig. 3(c) displays the emergence of a constitutive STAT1 DNA-binding complex in DG75 tTA LMP1 cells in the absence of tetracycline after 96 h. This observation was seen in unstimulated cells and the levels of DNA binding were comparable to those seen in the IARC-171 LCL. From these data, we conclude that LMP1 alone is sufficient for inducing a constitutive STAT1 DNA-binding complex that is unphosphorylated at tyrosine Y701.
STAT1 is constitutively serine-phosphorylated in LCLs, but lacks detectable lysine acetylation STAT1 may also be serine-phosphorylated at the Cterminal residue 727, and this type of modification is proposed to be important for full transactivation potential (Decker & Kovarik, 2000) . We compared serine phosphorylation of STAT1, following STAT1 immunoprecipitation, in the IARC-171 LCL and an EBV-negative Burkitt's lymphoma line, DG75. Nuclear extracts were generated from untreated or IFN-a-stimulated cells and incubated with 1 mg STAT1 antibody pre-coupled to Sepharose-protein G. Immunoprecipitated proteins were analysed by SDS-PAGE and Western blotting using specific antibodies to serinephosphorylated and pan-STAT1. Fig. 4(a) shows that STAT1 is constitutively serine-phosphorylated in both lines, although at a much higher level in the IARC-171 LCL, reflecting the higher levels of STAT1 in this line.
Given that STAT1 can bind DNA in the absence of tyrosine phosphorylation, we investigated whether DNA-bound STAT1 is serine-phosphorylated by using an EMSA. Nuclear extracts were generated from untreated and IFNa-stimulated IARC-171 LCL cells and were pre-incubated with 2 mg phospho-STAT1 (S727) antibody before 32 Pradiolabelled GRR probe was added (Fig. 4b) . The reduction in the intensity of the protein-DNA complex indicated that DNA-bound STAT1 in untreated and IFNa-stimulated IARC-171 LCL cells is serine-phosphorylated.
Both tyrosine and serine phosphorylation are key regulatory modifications of STAT1, but other post-translational modifications of STAT1 have been characterized. Arginine methylation of STAT1 at the N-terminal residue 31 has been documented and is believed to enhance the DNA-binding activity of STAT1 (Mowen et al., 2001) , although other studies have disputed these claims (Komyod et al., 2005; Meissner et al., 2004) . Lysine acetylation of STAT1 at residues 410 and 413 has recently been demonstrated and is believed to regulate the activity of NF-kB (Kramer et al., 2006) . To investigate whether STAT1 is acetylated in LCLs, we immunoprecipitated STAT1 from the nuclei of IARC-171 LCL cells that were untreated, stimulated with IFN-a and/or incubated with trichostatin A, a specific histone deacetylase inhibitor that has previously been shown to enhance STAT3 acetylation (Wang et al., 2005; Yuan et al., 2005) . Immunoprecipitates were analysed by SDS-PAGE and Western blotting using an antibody specific for acetylated lysine residues. The results showed that STAT1 lysine acetylation cannot be detected in the immunoprecipitates of nuclear extracts of IARC-171 LCL (Fig. 4c) , although the acetylation of an unidentified protein was observed in standard nuclear extracts. STAT1 acetylation was also not detected in immunoprecipitates of cytosolic extracts of this LCL (data not shown).
STAT1 is serine-phosphorylated downstream of PI3K and MEK and seems to restrict IFNstimulated STAT1 DNA binding
The observation of constitutive STAT1 serine phosphorylation in our LCL model led us to the question of which . Total lysates were generated from cells that were washed five times in RPMI 1640 medium and recultured in the presence of tetracycline (+) or absence of tetracycline for either 72 h ("3) or 96 h ("4). IARC-171 LCLs were used as a positive control for LMP1. These lysates were analysed by SDS-PAGE and Western blotting using antibodies specific to LMP1 and actin. Typically, 2¾10
5 cells were applied to each lane of the gel. These results are representative of three experiments. (b) STAT1 tyrosine phosphorylation and nuclear expression were measured in stable DG75 transfectants with inducible LMP1 expression. These cells were recultured in the presence of tetracycline (+) or absence of tetracycline for either 72 h ("3) or 96 h ("4). Cells were also incubated with IFN-a (1000 IU) for 30 min or left unstimulated. STAT1 tyrosine phosphorylation and nuclear expression were also measured in unstimulated IARC-171 LCL cells. Nuclear extracts were generated and were then analysed by SDS-PAGE and Western blotting using antibodies specific to phospho-STAT1 (Y701), pan-STAT1 and actin. Nuclear extract (10 mg) was applied to each lane of the gel. These results are representative of three experiments. (c) STAT1 DNA binding was measured in stable DG75 transfectants with inducible LMP1 expression by using an EMSA. These cells were recultured in the presence of tetracycline (+) or absence of tetracycline for either 72 h ("3) or 96 h ("4). STAT1 DNA binding was also measured in IARC-171 LCL cells. Cells were incubated with IFN-a for 30 min or left unstimulated. Nuclear extract (10 mg) was incubated with 2 ng 32 P-radiolabelled GRR oligonucleotide probe. Protein-DNA complexes were separated by using a native 4 % polyacrylamide gel and visualized by autoradiography. Only the protein-DNA complexes are shown, as free probe has been removed from the figure. The arrow indicates a specific protein-DNA complex. The results shown are representative of three separate experiments. serine kinase(s) regulates this process and whether it can be inhibited. Many kinases have been implicated in other cell models, including p38 mitogen-activated protein kinase (p38 MAPK) (Goh et al., 1999; Zykova et al., 2005) , extracellular signal-regulated kinase (ERK) (Zykova et al., 2005) and phosphatidylinositol 3-kinase (PI3K) (Nguyen et al., 2001; Rahimi et al., 2005; Zykova et al., 2005) . We used a selection of serine kinase inhibitors (all supplied by Calbiochem) to investigate their effect on IARC-171 LCLs: PD98059, a MEK1/2 inhibitor; staurosporine, a broadspectrum serine/threonine kinase inhibitor; and LY294002, a PI3K inhibitor. We found that staurosporine inhibited STAT1 serine phosphorylation, but also produced dramatic cytotoxicity to the cells (data not shown). However, PD98059 and LY294002 both inhibited STAT1 serine phosphorylation without causing dramatic cell death. We also found that, in combination, they further reduced the levels of STAT1 serine phosphorylation compared with that seen with the two inhibitors incubated alone (Fig. 5a ). As LY294002 has been shown to inhibit the phosphorylation of S6 ribosomal protein (Breslin et al., 2005) , phospho-S6
detection was used to demonstrate the actions of LY294002. Phospho-ERK detection was used to demonstrate the actions of PD98059. Thus, serine phosphorylation of STAT1 in our LCL model is sensitive to inhibition of both PI3K and MEK, suggesting that EBV stimulates serine phosphorylation through two distinct pathways.
Having shown earlier that DNA-bound STAT1 in EBVimmortalized LCLs was serine-phosphorylated, but not tyrosine-phosphorylated, we investigated whether inhibiting STAT1 serine phosphorylation in EBV-immortalized LCLs affected its DNA-binding capabilities. STAT1 DNA binding was analysed in IARC-171 LCLs that were either untreated or incubated with a combination of PD98059 and LY294002 for 24 h, and/or stimulated with IFN-a for 30 min, by EMSA (Fig. 5b) . The results show that inhibition of serine phosphorylation did not abrogate STAT1 DNA binding in untreated or IFN-a-stimulated IARC-171 LCL cells. In fact, surprisingly, inhibition of serine phosphorylation actually increased the amount of STAT1 DNA binding in IFN-a-treated cells. Interestingly, IFN-a treatment did not increase the amount of STAT1 found in nuclear extracts. This effect is attributed to the high levels of STAT1 that already exist in the nucleus of an LCL and shows that IFN-a does not stimulate further STAT1 nuclear translocation.
DISCUSSION
This study provides new evidence that STAT1 is capable of binding DNA in the absence of detectable tyrosine phosphorylation in EBV-immortalized LCLs. This form of constitutive STAT1 activation illustrates a new paradigm in STAT signalling in the context of EBV and adds to reports accumulating in the literature that describe gene expression regulated by unphosphorylated STATs. STAT1 lacking tyrosine phosphorylation has been shown to induce the constitutive expression of genes in other cells, including low-molecular-mass protein 2 (Chatterjee- Kishore et al., 2000) and the caspase 1-3 genes (Kumar et al., 1997) . Also, a role for STAT1 in the constitutive expression of major histocompatibility complex (MHC) class I antigens has been demonstrated in T lymphocytes (Lee et al., 1999) . Thus, STAT1 can drive gene transcription without requiring tyrosine phosphorylation to form classical homodimers. Unphosphorylated STAT3 has also been shown to activate oncogene expression through a mechanism distinct from that used by classical STAT3 dimers (Yang et al., 2005) . In the context of EBV-immortalized LCLs, MHC class I antigens are known to be elevated by LMP1 (Rowe et al., 1995) . Thus, LMP1-induced STAT1 may play a role in the regulation of genes such as MHC class I.
Although we have characterized a STAT1 DNA-binding complex lacking tyrosine phosphorylation in EBV-immortalized LCLs, this complex does not seem to exist in untreated BL41+B95.8 cells (Fig. 1b, c) . This observation conflicts with previously published data that show DNAbound STAT1 in untreated BL41+B95.8 cells (Richardson et al., 2003) . However, this contrast reflects the variable expression of LMP1 in these cells, as clones high in LMP1 display DNA-bound STAT1, whereas those low in LMP1 lack detectable STAT1 DNA binding. The role of LMP1 in this STAT1 DNA-binding complex is evident from the data These results are representative of four experiments. (b) The effect of serine phosphorylation on STAT1 DNA binding was measured in IARC-171 LCL cells by using an EMSA. These cells were unstimulated, treated with a combination of PD98059 (50 mM) and LY294002 (20 mM) for 24 h and/or incubated with IFN-a (1000 IU) for 30 min. Nuclear extract (10 mg) was then incubated with 2 ng 32 P-radiolabelled GRR oligonucleotide probe. Protein-DNA complexes were separated by using a native 4 % polyacrylamide gel and visualized by autoradiography. Nuclear extract (10 mg) was also analysed by SDS-PAGE and Western blotting using antibodies specific to STAT1 and actin. This demonstrates that the nuclear levels of STAT1 were equal in each sample analysed. The results shown are representative of five separate experiments. displayed in Fig. 3 . We have shown that LMP1 is sufficient to induce a constitutive STAT1 DNA-binding complex that lacks tyrosine phosphorylation. However, our hypothesis could be strengthened by depleting LMP1 from an LCL by RNA interference. We also have not ruled out the possibility that other STATs, such as STAT2 or STAT3, may comprise part of this complex. STAT1 is capable of forming STAT1-STAT2 and STAT1-STAT3 heterodimers, as well as forming classical STAT1 homodimers Zhong et al., 1994) . With regard to STAT3, we found, by immunoprecipitation, that it did not co-precipitate with STAT1 in the nuclei of IARC-171 LCL cells, even though it was both tyrosine-and serine-phosphorylated (data not shown). Only with further characterization will the function of this complex in EBV-immortalized LCLs be elucidated.
Constitutive serine phosphorylation of STAT1 has been observed in malignancies such as chronic lymphocytic leukemia (Frank et al., 1997) and Wilms' tumour (Timofeeva et al., 2006) . We provide further evidence that STAT1 is constitutively serine-phosphorylated in EBVinfected cells, agreeing with reports in the literature (Zhang et al., 2004) . Our data suggest that this phenomenon is not EBV-specific, as constitutive serine phosphorylation was also observed in the EBV-negative Burkitt's lymphoma cell line DG75 (Fig. 4a) . However, constitutive STAT1 DNA binding was seen in IARC-171 LCL cells, but not in DG75 cells, even though both cell lines exhibit serine-phosphorylated STAT1. This would suggest that DNA-bound serinephosphorylated STAT1 is a feature of EBV-immortalized LCLs. Also, as constitutive serine phosphorylation is absent in normal peripheral blood B lymphocytes (Frank et al., 1997) , this suggests that constitutive serine phosphorylation of STAT1 may be a feature of B-cell malignancy in general. Recent evidence has shown that serine-phosphorylated STAT1 promotes cell survival through the upregulation of two known pro-survival genes, MCL-1 and HSP-27 (Timofeeva et al., 2006) , indicating why malignant B cells may accumulate this molecular change.
Lysine acetylation of STAT1 has been demonstrated recently (Kramer et al., 2006) and could regulate its transcriptional abilities, as lysine acetylation of STAT3 has been shown to be vital for its DNA-binding and transcriptional capacity (Wang et al., 2005; Yuan et al., 2005) . Our evidence suggests that STAT1 is not lysine-acetylated in EBVimmortalized LCLs (Fig. 4c) . This observation would suggest that this modification is not necessary for STAT1 function in LCLs, although we do not rule out the possibility that we cannot detect it with the technology at our disposal. More specific antibodies for lysine-acetylated STAT1 may provide a different answer but, at present, do not exist commercially.
Many serine kinases have been implicated in catalysing STAT1 serine phosphorylation in various cell systems. We have shown that the constitutive serine phosphorylation of STAT1 in LCLs is abrogated following long-term treatment with inhibitors of PI3K and MEK (Fig. 5a ). Both of these enzymes have also been implicated by other studies (Nguyen et al., 2001; Rahimi et al., 2005; Zykova et al., 2005) . Long-term treatment was necessary to ensure sufficient inhibition of STAT1 serine phosphorylation, as shorter incubation times yielded very little or no effect (data not shown). It is possible that this may reflect some form of indirect mechanism or perhaps just a slow inhibitory effect by PD98059 and LY294002 in combination. This is highlighted by the fact that staurosporine, a broadspectrum serine/threonine kinase inhibitor, caused rapid inhibition after only 1 h (data not shown). By inhibiting STAT1 serine phosphorylation in LCLs through use of the combined incubation of PD98059 and LY294002, we have shown increased STAT1 DNA binding in LCLs stimulated with IFN-a (Fig. 5b) . This provides evidence that the constitutive serine phosphorylation of STAT1 in LCLs may have a repressive effect on IFN-a-induced STAT1 signalling. Repression of STAT signalling has been linked to serine phosphorylation and suggests that its role is more complex than thought previously (Bowman et al., 2000) . STAT3 serine phosphorylation has been shown to prevent tyrosine phosphorylation and DNA binding through either a direct influence upon or an indirect negative interaction with upstream tyrosine kinases (Chung et al., 1997; Jain et al., 1998; Sengupta et al., 1998) . Our data agree with these findings, in that serine phosphorylation seems to repress STAT1 DNA binding in IFN-a-stimulated LCLs. This effect could explain why no constitutive STAT1 tyrosine phosphorylation was seen in our LCLs (Fig. 1a) . These observations provide new data supporting a repressive role of serine phosphorylation on STAT1 rather than an enhancing role, and may indicate some form of reprogramming in IFN signalling by EBV.
In summary, this study builds on previous reports by being the most complete survey of post-translational modifications of STAT1 in EBV-immortalized LCLs. Our work illustrates three key advances in our knowledge. Firstly, we have shown that LMP1-induced STAT1 lacks tyrosine phosphorylation and lysine acetylation, but is capable of binding DNA. Secondly, we have also demonstrated, for the first time in EBV-immortalized LCLs, that the serine phosphorylation of STAT1 is regulated by two distinct pathways, PI3K and MEK. Thirdly, and most surprisingly, this modification appears to repress the DNA binding of IFN-stimulated STAT1. This indicates that STAT1 may be subject to some form of viral reprogramming by EBV during cellular transformation.
